Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q4 2023 Earnings Call Transcript March 28, 2024 8:00 AM ET
Company Participants
Alex Lobo - Stern Investor Relations
Milton Werner - CEO
Garth Lees-Rolfe - CFO
Conference Call Participants
Operator
Ladies and gentlemen, thank you for standing by. Greetings, and welcome to Inhibikase Therapeutics Fourth Quarter and Full Year 2023 Financial Results. At this time, all participants will be in listen-only mode. A question-and-answer session will follow the formal presentation. Please note that today's conference is being recorded. [Operator Instructions]
I'll now turn the call over to Alex Lobo, Stern Investor Relations. Alex, you may now begin.
Alex Lobo
Thank you, operator. Good morning, and welcome to Inhibikase Therapeutics fourth quarter and full year 2023 financial results conference call and audio webcast. With me today is Dr. Milton Werner, Chief Executive Officer; and Garth Lees-Rolfe, Chief Financial Officer.
On March 27, Inhibikase issued a press release announcing financial results for the fourth quarter and full year ended December 31, 2023. We encourage everybody to read yesterday's press release as well as Inhibikase's annual report on Form 10-K, which is being filed with the SEC.
The company's press release and annual report are also available on Inhibikase's website at inhibikase.com. In addition, this conference call is being webcast through the Investor Relations section of the company's website and will be archived there for future reference.
Please note that certain information discussed on today's call is covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Participants are cautioned that this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, March 28, 2024. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. Information on potential risks and uncertainties are set forth in our most recent public filings with the SEC at sec.gov. The company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this webcast, except as may be required by applicable securities laws.
With that said, I would now like to turn the call over to Dr. Milton Werner. Milton, you may begin.
Milton Werner
Thank you, Alex, and thank you, everybody, for joining the call today. Before I begin, I just want to give a round of applause to our outgoing Chief Financial Officer, Joe Frattaroli, who is on the call. Tomorrow will be his last day with the company and we are very grateful for the six years of work that he and I have done together to bring Inhibikase where we are.